2 Under-the-Radar Stocks to Buy and Hold

Axsome Therapeutics reported Q2 revenue of $218.4 million, up 46% year over year, including Auvelity sales of $180.3 million, up 51%; its late-stage pipeline and potential new indications could support continued growth. Exelixis Q2 revenue rose nearly 11% to $628.7 million, with U.S. generic competition for Cabometyx not expected before 2030 following court victories. Exelixis also faces an FDA review extension for zanzalintinib, shifting the decision deadline from December 3, 2026, to March 3, 2027, while the article describes its trial results as mixed but encouraging.

Analysis

The key distinction is what must go right for each equity: AXSM needs sustained conversion of a concentrated commercial base into durable, diversified earnings; EXEL needs to bridge a finite patent runway with pipeline assets while preserving the value of its lead franchise. For AXSM, the market mechanism is operating leverage in either direction: if new-indication uptake and prescribing persist, incremental revenue can improve the earnings trajectory; if uptake disappoints, concentration makes any slowdown more visible. Phase 3 initiation for smoking cessation is an option, not near-term revenue evidence. Track prescription trends, payer access, and launch spending alongside reported sales.

EXEL has a nearer, binary event path. The FDA review extension should be treated as added uncertainty, not evidence of either approval or rejection. The November patent trial could change the expected duration of U.S. exclusivity, while zanzalintinib’s mixed trial read-through makes pipeline replacement value difficult to underwrite as assured. A win on one front does not eliminate risk on the other.

Contrarian angle: optimistic pipeline narratives can obscure the gap between clinical progress and commercial contribution. Conversely, an FDA delay alone may be overinterpreted if the application remains approvable; verify the agency’s stated reason and any request for additional data. Without valuation, cash-flow, and consensus estimates, neither article supports an unconditional buy. Over 1–3 months, prioritize EXEL’s litigation and regulatory updates; over 6–18 months, test AXSM’s launch durability and whether either company demonstrates credible revenue diversification.

Key Decisions for Investors

• AXSM — Watch for a pullback rather than chase the bullish pipeline narrative. Consider a staged long only if Auvelity demand remains firm in upcoming reports and commercial growth is not being offset by a deteriorating expense trajectory. Falsify the thesis if sales growth materially decelerates or access/prescribing indicators weaken; verify those data before sizing.
• EXEL — Keep exposure event-sized into the November patent trial and the March 3, 2027 FDA decision; avoid treating either outcome as assured. A favorable patent outcome plus a clear regulatory path could support the bridge beyond Cabometyx. Reassess promptly on an adverse court ruling, an FDA request that implies meaningful additional work, or weaker-than-expected clinical evidence.
• No forced pair trade: AXSM and EXEL have different catalysts, and the article supplies no valuation, cash-flow, or positioning data to establish relative mispricing. Use XBI only as a broad biotech risk benchmark, not as a direct hedge for either company’s company-specific event risk.
• Alert: before adding either name, verify AXSM’s indication-level commercial contribution and launch costs, and EXEL’s patent scope, trial details, and the FDA’s reason for extending review. These missing items determine whether the pipeline optionality is investable or already being asked to carry too much of the thesis.